Evolution of RX IB Over The Years?

I'm in a typical IB coverage group, but I have always been interested in restructuring. The prior and current years have been interesting times in the market, and it feels like the space is evolving with the explosive growth of ABL usage and LMEs. Given the changing dynamics, have you guys seen any observable changes in your restructuring groups over the years? 

Is there more fee desirability of doing out-of-court restructuring transactions? Are there MDs who are beginning to carve out niches for LME transactions? Are the average chapter-11 restructuring transactions becoming larger due to the additional tools to fend off bankruptcy?  

4 Comments
 

Restructuring investment banking (RX IB) has indeed evolved significantly over the years, shaped by market dynamics, economic cycles, and the increasing complexity of financial instruments. Here's a breakdown of the key trends and changes observed in RX IB:

1. Cyclicality and Market Dynamics

  • Restructuring is highly cyclical, with activity levels closely tied to economic downturns. For instance, during periods of distress like 2008-2010 and 2015-2016, RX activity surged, leading to higher pay and better exit opportunities for professionals in the space.
  • The current market, with the rise in ABL (Asset-Based Lending) usage and Liability Management Exercises (LMEs), reflects a shift towards more creative and proactive financial solutions to avoid outright bankruptcy.

2. Out-of-Court Restructurings

  • There is a growing preference for out-of-court restructuring transactions. These deals often avoid the publicity and costs associated with formal bankruptcy proceedings, making them more desirable for both clients and advisors.
  • Many RX deals, especially out-of-court ones, do not make it to league tables or public announcements, emphasizing the importance of networking and direct insights from professionals in the field.

3. Specialization and Niche Carving

  • Managing Directors (MDs) are increasingly carving out niches, particularly in areas like LMEs. This specialization allows them to differentiate themselves and their groups in a competitive market.
  • RX groups are also becoming more focused on specific industries or transaction types, such as distressed debt, recapitalizations, or operational turnarounds.

4. Size and Complexity of Transactions

  • The average size of Chapter 11 restructuring transactions has grown, partly due to the availability of tools like LMEs and other financial engineering strategies that help companies delay or avoid bankruptcy.
  • This trend reflects the increasing complexity of RX deals, requiring bankers to have a deep understanding of both financial and operational restructuring.

5. Exit Opportunities and Prestige

  • RX remains a specialized field with strong exit opportunities, particularly to distressed debt funds and private equity. The skill set developed in RX, including financial modeling and problem-solving under pressure, is highly valued in the buy-side community.
  • Top RX groups like PJT, Houlihan Lokey, Lazard, and Moelis continue to dominate the space, with their reputation and deal flow making them attractive destinations for aspiring RX bankers.

6. Big 4 and Mid-Market Dynamics

  • While Big 4 firms focus more on operational restructuring and mid-market companies, RX IB groups at top banks handle larger, more complex financial restructurings. This distinction has remained consistent over the years.

In summary, RX IB has evolved to adapt to changing market conditions, with a noticeable shift towards out-of-court solutions, increased specialization, and larger, more complex transactions. For someone in a coverage group looking to transition into RX, staying informed about these trends and networking with professionals in the space can be invaluable.

Sources: Thoughts on Restructuring Groups?, Top Restructuring Groups 2016, Top Restructuring Groups 2019 & Restructuring Questions, Top Restructuring Groups 2019 & Restructuring Questions, Restructuring Groups 2020

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

I can maybe hop in (as a first year though I may not be able to give you as much depth as you’d hoped, but I’ll do my best). I think the general notion wrt to restructuring has been that advisors who staked out a corner of the sponsor-backed distressed activity years ago are really reaping the profits. Back near when LTCM exploded and for the following 10-15 years so-called “fallen angels” led the restructuring world with the largest fees and most lucrative advisory roles. However, the rise of PE (and widespread use of high amounts of leverage) brought a new form of customer for RX shops to build relationships with - sponsors. Not only were they repeat customers, but their business model was predicated on treating equity as a call option (thus potentially forgoing positive NPV projects in lieu of risky undertakings - apologies for my theory here). The world of sponsors has also brought forth the concept of LMEs, since more DIP/distressed equity holders now have greater skin in the game wrt preserving equity value over performing their true fiduciary duty in the zone of insolvency. Combined with the absurd increase in bankruptcy costs and high business deterioration risk, out of court capital solutions have become much more core to distressed company toolkits. This has led to a narrower interpretation of debt docs that has then led to transaction structuring which “shifts” recovery value from senior capital structure constituents to junior call options. Something interesting going on in RX end-markets (or distressed entities) has been the rise of private credit essentially offering low-differentiated financing packages to sponsors. This has subsequently led to sponsor financing suppliers having to differentiate and win lending opportunities by compressing on low-hanging fruit (credit doc protections, since this doesn’t damage their returns in the immediate future). Thus LME opportunities continue to be plentiful when it would seem counterintuitive to permit issuing financing withouta JCREW blocker to a retail company with core crown jewel asset and permissible investment basket capacity. Sorry for the dump but let me know if helpful - honestly would love to hear what some of the more senior people have to contribute!

 
Most Helpful

Excepturi sed veniam eveniet id. Labore incidunt autem et id dolorem eum neque. Dolores nisi doloribus ut eos non. Incidunt amet autem nemo voluptatem et assumenda officiis.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 02 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • Morgan Stanley 05 98.3%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (44) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (78) $151
  • Intern/Summer Analyst (72) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
DrApeman's picture
DrApeman
98.9
7
dosk17's picture
dosk17
98.9
8
CompBanker's picture
CompBanker
98.9
9
GameTheory's picture
GameTheory
98.9
10
Mimbs's picture
Mimbs
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”